Valneva Usa, Inc.

Bethesda, MD Doing business as Intercell USA Inc. Part of Valneva

UEI
NT38AFWQNKM7
CAGE
43FM1
Primary NAICS
325412 Pharmaceutical Preparation Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Foreign Owned
Entity structure
Corporate Entity (Not Tax Exempt)
Corporate family
  • Valneva Parent Saint-Herblain, Pays de la Loire R3LYSVWSJKL7
    • Intercell USA Inc.
SAM.gov registration date
Physical address
4550 Montgomery Ave #460, Bethesda, MD 20814, USA
Website
valneva.com
Founded
2013
Employees
251-1K
Estimated annual revenue
$100M-$250M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $21,768,836
FY2025 $18,449,353
FY2024 $39,391,577
FY2023 $10,075,964

Top agencies by obligations

Rank Agency Obligated, FY2026–FY2027 Share
1 Defense Logistics Agency $20,753,107
2 Department of Veterans Affairs $710,457
3 Department of Health and Human Services $295,272
4 Department of Justice $10,000

Contract vehicles

Contract awards

Award Agency Obligated Awarded
Japanese encephalitis vaccine "ixiaro" 7571MN26P00043 Assistant Secretary for Financial Resources $120,296
Medical supplies - vaccine 15F06726P0000246 Headquarters Division (FBI) $10,000
Japanese encephalit SPE2DP26F1837 Medical Supply Chain (DLA) $5,148,058
Japanese encephalit SPE2DP26F1838 Medical Supply Chain (DLA) $2,941,747
Japanese encephalitis vaccine for state department 75P00226P00005 Office of the Assistant Secretary for Administration $174,976

Latest 5 listed here. See the rest on GovTribe.

Grant awards

Award Agency Obligated Awarded
Development of anthrax vaccine sink-patch W81XWH0810267 Department of Defense $630,371

Similar vendors

About the company

Valneva USA, Inc., doing business as Intercell USA Inc., is a specialty vaccine manufacturer and foreign-owned subsidiary of French-based Valneva SE that operates exclusively as a prime contractor supplying Japanese encephalitis vaccine (IXIARO) and other immunological products to federal agencies on a firm fixed-price basis. The company competes full-and-open with no set-aside designation across the vast majority of its federal portfolio, though two small recent purchase orders (totaling $347,272) carry Total Small Business set-aside designations.

Valneva USA's federal footprint is heavily concentrated in a single customer and product line. The Defense Logistics Agency Troop Support Medical accounts for 51 of 157 total awards and $730.5 million of the $870.4 million combined potential value across the portfolio — 84% of dollars. The company's three primary indefinite delivery vehicles with DLA Troop Support Medical are valued at $49.3 million (single-award IDC, awarded January 29, 2025, completion January 28, 2026), $48.0 million (single-award IDC, awarded September 22, 2023, completion September 21, 2024), and a third vehicle referenced in award narratives at approximately $165.9 million, collectively enabling delivery orders for IXIARO vaccine to support the Department of Defense medical countermeasures program. Recent representative DLA work includes an $8.25 million delivery order (October 23, 2025) for IXIARO, a $5.15 million delivery order (January 22, 2026) for Japanese encephalitis vaccine, and a $4.41 million delivery order (January 7, 2026) for the same vaccine. The Department of Health and Human Services Office of the Assistant Secretary for Administration represents the second customer by volume (63 awards) but only $3.8 million in combined potential value, reflecting a pattern of small, frequent orders for IXIARO vaccine stock against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The Department of Veterans Affairs Veterans Integrated Service Network 12 represents 25 awards valued at $8.9 million, issued under the same GSA Schedule vehicle. The Department of Justice Federal Bureau of Investigation maintains a Blanket Purchase Agreement with Valneva USA for a range of vaccines including hepatitis A and B, MMR, tetanus, diphtheria, meningitis, rabies, polio, typhoid, and yellow fever, with 10 awards totaling $500 thousand. Concentration is extreme: the top two customers (DLA and HHS ASA) account for 114 of 157 awards and approximately $734.3 million of $870.4 million in potential value.

Valneva USA holds a Department of Veterans Affairs Federal Supply Schedule contract for Pharmaceuticals and Drugs (ceiling $4,026,865, expiring September 28, 2030) awarded September 29, 2025. The company's primary contracting vehicles are DLA Troop Support Medical indefinite delivery contracts, each yielding multiple firm fixed-price delivery orders throughout their performance periods. The company is the sole supplier on its major DLA IDCs, reflecting single-award vehicle status. Recent activity has been consistent but flat — 10 awards in 2024 and 10 awards in 2025 — with 157 total awards spanning back to 2007 and $330.8 million in obligated dollars representing 38% of potential value. Only three awards face ultimate completion within the next twenty-four months, carrying $841 thousand in combined potential value, presenting minimal near-term recompete exposure.

The firm's capability footprint is narrow and specialized. The vendor portfolio is dominated by Pharmaceutical Preparation Manufacturing NAICS (88 awards) and Biological Product Manufacturing NAICS (48 awards), with 144 awards classified under PSC Drugs And Biologicals. Beyond IXIARO, Valneva USA has delivered Chikungunya vaccine in small quantities and maintains an uncommitted BPA with FBI for a broad range of vaccines, but DLA procurement of Japanese encephalitis vaccine accounts for the vast majority of federal revenue. Place of performance is consistently Bethesda, Maryland, with references to a Potomac, Maryland facility in some award narratives. Valneva USA carries no federal subcontractors across its visible award portfolio and operates all work in-house. As a subsidiary of Valneva SE, a specialty vaccine manufacturer, Valneva USA functions as the U.S. distribution and contracting arm for a product portfolio focused on infectious disease vaccines with significant military readiness and public health implications.

Quick answers

Is Valneva Usa, Inc. registered in SAM.gov?

Yes. Valneva Usa, Inc.'s SAM.gov registration is active through March 20, 2027.

What is Valneva Usa, Inc.'s CAGE code?

Valneva Usa, Inc.'s CAGE code is 43FM1, and its Unique Entity ID (UEI) is NT38AFWQNKM7.

Which contract vehicles does Valneva Usa, Inc. hold?

Valneva Usa, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.

How much has Valneva Usa, Inc. received in federal contracts?

Federal contracts obligated $18,449,353 to Valneva Usa, Inc. in fiscal year 2025 and $89,685,730 in fiscal years 2023 through 2027.

How does Valneva Usa, Inc. rank among federal contractors?

Valneva Usa, Inc. ranked #21 in PSC 6505, #27 in NAICS 42345 and #29 in NAICS 4234 in FY2025.

What is Valneva Usa, Inc.'s most recent federal award?

Valneva Usa, Inc.'s most recent federal contract award is Japanese encephalitis vaccine "ixiaro" (7571MN26P00043), from Assistant Secretary for Financial Resources, on June 18, 2026.

On GovTribe

See Valneva Usa, Inc.'s full federal record

  • Federal contract awards
  • IDV awards
  • Contract vehicles
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors

Find teaming partners on GovTribe